Year: 2025
Type: article
Abstract: Approximately 1% to 2% of the population reports a cephalosporin allergy label (CAL).1 However, many of these labels are misclassified as allergies, and only approximately 8% of CALs correlate with positive skin testing.1 Furthermore, individuals with true prior IgE- mediated reactions, estimated to be 10%/year or higher, may have loss of hypersensitivity over time and are not truly allergic when tested and rechallenged.2 Carrying a label of cephalosporin allergy is consequential and often leads to treatment with alternative agents with inferior outcomes, infections owing to multidrug-resistant organisms, and higher health care–related costs.
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Funders: Foundation of the American College of Allergy, Asthma & Immunology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Northern Ireland Connected Health Innovation Centre, Murdoch University, National Institutes of Health, Agency for Healthcare Research and Quality, American Academy of Allergy, Asthma and Immunology Foundation, National Health and Medical Research Council, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Awards: G129402337, G1991070941, G3702547411, Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and Community, Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors, A Translational Bioinformatics Approach for Phenotyping and Genetic Risk of Severe Cutaneous Adverse Drug Reactions, Immune Tolerance Network, Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study), NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, Vanderbilt University Medical Center (VUMC) CoFAR Clinical Research Center, G900905269
OpenAlex ID: W4411079307